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The objective of this study was to examine the suita-
bility of multiplex ligation-dependent probe amplifi-
cation (MLPA) in chorionic villus samples as a
replacement for traditional karyotyping for the detec-
tion of (an)euploidies of chromosomes 21, 18, 13, X,
and Y. Chorionic villus samples were diagnosed by
traditional karyotyping using short-term cultures
(STC) and long-term cultures (LTC), and by MLPA
using kit P095. DNA was extracted after digestion of
whole villi with proteinase K and/or trypsin and col-
lagenase. Different cell-dissociation procedures were
tested to obtain MLPA results representative of the
cytotrophoblast layer and the mesenchymal core.
Over 95% of the MLPA results were in concordance
with the traditional karyotyping of STC and LTC. Tra-
ditional karyotyping revealed seven mosaics. After
digestion of whole villi with proteinase K, only ab-
normal cell lines confined to the STC gave rise to
abnormal MLPA results. In one sample, the complete
discrepancy between STC and LTC was resolved after
enzymatic dissociation of cells from the cytotropho-
blast layer and the mesenchymal core. MLPA in cho-
rionic villus samples was found to be a reliable test for
the detection of (an)euploidies of chromosomes 21,
18, 13, X, and Y. Whole villi digestion with proteinase
K resulted in the over-representation of cytotropho-
blasts in the DNA pool. To obtain MLPA results repre-
sentative for STC and LTC, enzymatic dissociation of
cells from the cytotrophoblast layer and mesenchy-
mal core is required. (J Mol Diagn 2009, 11:17–24; DOI:
10.2353/jmoldx.2009.070140)
Chorionic villus sampling has been widely accepted as a
technique for first trimester prenatal diagnosis and is
performed from 11 weeks of gestation. Until recently,
prenatal diagnosis of chorionic villus samples (CVS) was
accomplished through tissue culture and subsequent cy-
togenetic analysis. This procedure is labor intensive and
time-consuming. Therefore, more rapid and comprehen-
sive methods for the prenatal diagnosis of CVS are cur-
rently being developed and implemented. In a number of
prenatal centers in Europe, quantitative fluorescent PCR
(QF-PCR) analysis is already being offered to women
undergoing invasive testing by chorionic villus sam-
pling.1 In parallel, we have implemented multiplex liga-
tion-dependent probe amplification (MLPA) for the rapid
detection of (an)euploidies of chromosomes 21, 18, 13,
X, and Y in amniotic fluid cells.2–4 A general disadvan-
tage of the use of CVS in comparison with amnion fluid is
the extra-embryonic nature of this tissue. Although fetus and
placenta originate from the same zygote, a discrepancy
between the chromosomal constitution of cells in the pla-
centa and cells in the fetus, known as chromosomal mosa-
icism, can occur. Such mosaicisms are well documented in
the literature and are detected in 1% to 2% of the CVS.5,6
Abnormal mosaic cells can be found in both fetal and
placental tissues, or may be confined to either the placenta
(confined placental mosaicism, cpm) or the fetus.7 Karyo-
types of CVS represent cells from chorionic ectoderm (cy-
totrophoblasts) in short-term cultures (STC) and chorionic
mesoderm (mesenchymal core) in long-term cultures (LTC).
In molecular testing of CVS it is, therefore, of obvious im-
portance to establish that both cell lineages are adequately
represented by the pool of cells from which the DNA is
extracted.8 In this study we investigated the suitability of the
MLPA test for the detection of (an)euploidies in CVS and
assayed to what extent this test compares to traditional
karyotyping (TK) of STC, LTC, or both.
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Materials and Methods
Clinical Samples
CVS with a weight of 30 mg (N  152), were collected
at the outpatient clinics located in Nijmegen, Arnhem,
Tilburg, ‘s-Hertogenbosch and Enschede (Network Pre-
natal Diagnostics Nijmegen, the Netherlands) from preg-
nant women at 11 to 21 weeks of gestation. From these
152 CVS, 125 were consecutively collected between May
2006 and June 2007. Additionally, twenty CVS with
known aneuploidies for one of the target chromosomes
and seven CVS diagnosed by TK as mosaic were added.
The referral reasons of the pregnant women ranged from
low-risk to high-risk. The CVS were washed in PBS and
the villi were separated from maternal decidua and blood
clots under an inverted microscope.
Karyotyping
Approximately 20 to 30 mg of the villi was used for
conventional karyotyping according to standard STC and
LTC procedures. Briefly, 10 to 15 mg of the villi was used
for STC and, subsequently, incubated for 30 minutes in
colcemid, followed by a short hypotonic treatment after
which the cells were fixed in methanol/acetic acid (3:1)
and rehydrated. Finally, the trophoblast (interphase and
metaphase) cells were released from the villus core using
60% acetic acid and spread on microscopic slides. The
remaining 10 to 15 mg of the villi were used for LTC, after
incubation for one hour in trypsin-EDTA and a 40-minute
incubation in collagenase. Metaphases were harvested in
situ using standard procedures on Labtek II chamber
slides. Cytogenetic investigation of STC and LTC was
routinely performed and 4 and 8 metaphases were ana-
lyzed, respectively, to exclude discrepancies between
STC and LTC.9 Cytogenetic examination of the LTC was
expanded to 29 metaphases when an abnormal karyo-
type was detected in STC or LTC cells. CVS karyotypes
with a tetrasomy or triploidy were excluded from this
study.
Definition of Mosaic Levels
CVS encompass cells from both the trophoblasts and the
mesenchymal core. Discordant findings between STC
and LTC and/or fetal tissues have been either referred to
as pseudomosaicisms or true mosaicisms.10 Here, three
levels to define mosaicism were used: level I, detection of
a single abnormal cell (single cell pseudomosaicism),
level II, the same abnormality was detected in two or
more cells in the same culture vessel (multiple cell
pseudomosaicism) or level III, the same abnormality was
observed in two or more independent culture vessels
(true mosaicism).10 Discrepancies between karyotypes
of villus and fetal tissues may occur as a result of a cpm.
Three types of cpm can be discerned and categorized by
the placental cell lineage exhibiting the abnormal cell
line, ie, confined to the cytotrophoblast (type I), the mes-
enchymal core (type II), or both (type III).5
Fluorescence in Situ Hybridization Analysis
Interphase fluorescence in situ hybridization (I-FISH)
analyses were performed on nuclei (N  100) of STC villi
cells in samples exhibiting a mosaicism of any of the
target chromosomes using an AneuVysion prenatal de-
tection kit (Vysis Inc, Downers Grove, Ilinois) for an ac-
curate establishment of the distribution of normal and
abnormal cells.
DNA Extraction Following Proteinase K
Treatment of Whole Villi
This method was used for all CVS. DNA from at least two
chorionic villi was extracted using a QIAamp DNA Mini Kit
(Qiagen) following the protocol “Isolation of DNA from
soft tissues using the TissueLyser and QIAamp DNA Mini
Kit” (Qiagen, Westburg bv, The Netherlands) In this pro-
cedure, incubation at 56°C with proteinase K results in
lysis of the villi before DNA extraction. Proteinase K has a
specific activity and degrades tissue to facilitate the pu-
rification of the DNA. Finally, DNA was eluted in 50 l AE
buffer (10 mmol/L Tris-HCl, 0.5 mmol/L EDTA, pH 9.0).
The DNA was quantified using a Nanodrop spectropho-
tometer (NanoDrop Technologies Wilmington, Delaware)
and varied from 2.5 to 650 ng/l elution buffer.
DNA Extraction Following Enzymatic
Dissociation of Villi
Two methods were designed to obtain cell populations
from the cytotrophoblast layer and the mesenchymal
core separately. In the first method, a modification of the
method described by Mann,8 ie, digestion of cleaned villi
with collagenase (800 units/ml; 37°C, 30 minutes), was
followed by trypsin digestion (0.5% trypsin/EDTA, 37°C,
30 minutes). After collagenase digestion, the suspension
was separated from the remaining villi and transferred to
a tube containing 4 ml PBS and 10% fetal calf serum to
stop the digestion. After centrifugation (1200 rpm, 5 min-
utes) the supernatant was removed and the cell pellet
was re-suspended in 300 l PBS (fraction C). After di-
gestion of the remaining villi with trypsin, 4 ml PBS 10%
fetal calf serum were added to stop the reaction. After
centrifugation (1200 rpm, 5 minutes) the supernatant was
removed and the cell pellet was re-suspended in 300 l
PBS (fraction M). Finally, 100 l of fraction C and 100 l
of fraction M were mixed (1:1) (fraction T) and used for
DNA isolation as described below.
In the second method, digestion of cleaned villi was
first performed with trypsin (0.5% trypsin/EDTA, 37°C, 1
hour) followed by collagenase digestion (800 units/ml;
37°C, 40 minutes). After both digestion steps, cell frac-
tions C, M, and T were obtained as in the first method.
DNA extractions were performed by incubation of the
cell population with proteinase K at 56°C. DNA was pu-
rified using a QIAamp DNA Mini Kit (Qiagen) following the
protocol “Blood and body fluid spin protocol.” Finally,
DNA was eluted in 50 l AE buffer (10 mmol/L Tris-HCl,
0.5 mmol/L EDTA, pH 9.0).
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Both methods were performed on CVS case 7 with
discrepant results in STC and LTC, ie, 46,XY and
47,XY,18, respectively.
MLPA Test
The MLPA test was performed with SALSA MLPA kit P095
for aneuploidy detection as described by Schouten
(MRC Holland, Amsterdam, The Netherlands).11 The
MLPA analyses were performed blinded to the cytoge-
netic analyses until completion. Data analyses were
performed on the transfer of electropherogram-based
GeneMapper results to a modified spreadsheet for nor-
malization and ratio computation of the peak areas
(Kooper et al, submitted). First an intrasample normalization
of each probe peak area was performed, followed by an
intersample normalization with tray-specific references.
Normalization is essential because variations in experimen-
tal conditions may lead to quantitative differences.
As a consequence of our normalization procedure,
mean probe ratios skew in case of a trisomy, since the
probe ratios of the targets with two copies scale down to
80% when a trisomy for one of the targets is present. This
decrease in mean probe ratios is not corrected in the
data analysis. The mean and SD of each target chromo-
some were determined, followed by a 95% confidence
interval (CI). In cases of disomy (two copies of each
target chromosome), these calculations will result in a
theoretical (expected) value of 1.0, representing two cop-
ies of the target sequence in the sample. One or three
copies of the target sequence in a sample will result in
theoretical values of 0.5 or 1.5, respectively. A result is
considered abnormal when the theoretical value (
expected value in a normal case) is not included in the
confidence interval and the mean probe ratio is more or
less than 10% of the expected value. Follow-up of
these samples is performed by karyotyping and/or
amniocentesis.
MLPA does not detect female triploidies. As a conse-
quence of the normalization procedure ie, relative peak
areas do not differ in intrasample normalizations as the
copy numbers of all of the targets is the same. A male
triploidy will yield normal mean probe ratios for 21, 18,
and 13, an increased mean probe ratio for X and a
decreased mean probe ratio for Y. In addition, there is
limited potential to discriminate maternal contamination in
a normal male sample from 69,XXY and, therefore, care-
ful CVS cleaning before sample preparation is of critical
importance.
The Levene’s test was used to determine equality of
variances of the pooled standard deviations of the mean
probe ratios for the target chromosomes 13, 18, 21, and
X between CVS and amniotic fluid samples.
Results
Proteinase K Treatment of Whole Villi
In all 152 CVS, the MLPA test was performed success-
fully. The results were compared with cytogenetic analy-
ses of both STC villi and LTC villi. There was a correct
assignment of sex in all 152 samples. No evidence for the
presence of maternal contamination was noted in male
samples, ie, the expected normalization effect of a de-
creased mean probe ratio for the Y chromosome com-
bined with an increased mean probe ratio for the X chro-
mosome was observed in none of the male samples.
A summary of the test results on all 152 samples is
displayed in Figure 1, showing a boxplot with the mean
ratios for the chromosome 21, 18, 13, X, and Y probes in
euploid (N 124: normal male N 58 and normal female
N  66), aneuploid (N  21), and (pseudo)mosaic sam-
ples (N  7). In all normal samples, the mean ratios for
the autosomes were close to the expected value of 1.0.
The mean probe ratios for samples with a trisomy 21, 18,
or 13 were all significantly increased (mean ratios of1.0
with 95% CI not including 1.0) and close to the expected
value of 1.5. In all normal male and female samples the
mean probe ratios for X and Y were close to the expected
values: 1.0 for X in female samples and 0.5 for X and Y in
male samples, and for X in samples with a monosomy X.
The variation in mean probe ratios was slightly higher for
Y, which may be due to the limited number of targets
included in the P095 kit for this chromosome.
Figure 1. Quantitative MLPA analysis with mean probe ratios of the 21, 18,
13, X, and Y targets with 50% of the samples within the box. The outliers are
cases ‘o’ with values between 1.5 and 3 box-lengths from the boundaries of
the box. Case 3 shows an increased mean probe ratio for chromosome 21 of
1.24 (95% CI, 1.021.46). Inspection of individual probe ratios of this chro-
mosome showed an increase for all individual probes, indicative for a mosaic
of trisomy 21. Case 7 is illustrated as an extreme (*) in the box plot with an
increased mean probe ratio for chromosome 18 of 1.18 (95% CI, 1.081.28),
ie, this ratio is increased for the expected value of 1.0 for a disomy 18 and
decreased for the expected ratio of 1.5 for a trisomy and, therefore, indicative
for a mosaic trisomy 18. Case 1 is illustrated as an extreme (*) in the box plot
with a mean probe ratio for the Y chromosome of 0.17 (95% CI, 0.140.21).
Case 2 is illustrated as an outlier ‘o’. The mean probe ratio for X is 0.80 (95%
CI, 0.700.90), ie, this ratio is increased for the expected value of 0.5 for a
monosomy X and decreased for the expected ratio of 1.0 for a disomy and,
therefore, indicative for a mosaic 45,X/46,XX. The other outliers in the box
plots result in increased or decreased mean probe ratios, all related to broad
confidence intervals. The expected values of 0.5, 1.0, or 1.5 are within the
confidence intervals in all outliers.
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Normal Karyotypes
In 124 of the CVS the normal results of MLPA and TK were
in concordance for all five target chromosomes (58 and
66 male and female samples, respectively).
Aneuploidies in both STC and LTC
In total, 21 aneuploidies for one of the target chromo-
somes were detected; one with trisomy 13, five with tri-
somy 18, ten with trisomy 21 and five with monosomy X.
There was complete concordancy between the MLPA
and TK results. In all 145 non-mosaic samples, the unex-
plained SD of the mean probe ratio for the target chro-
mosomes 13, 18, 21 and X turned out to be 0.041. The Y
chromosome was excluded in this calculation because of
the presence of only four probes (see above). This resi-
dual variation was significantly lower (P  0.001, using F
test to compare two variances) than the corresponding
value of 0.068 determined in a set of amniotic fluid sam-
ples (Kooper et al, submitted).
(Pseudo)mosaicisms
Seven samples displayed discordancies between TK
(STC and/or LTC) and MLPA. The results of TK (STC and
LTC), I-FISH, referral reason, gestational age and fol-
low-up of these cases are summarized in Table 1. MLPA
results of these mosaic cases were compared with the TK
results (golden standard) and are summarized in Table 2.
Case 1: STC villi showed a mosaic karyotype 45,X[2]/
46,XY[1] and a normal karyotype in LTC. I-FISH of STC
nuclei resulted in a test failure. The MLPA results showed
a decreased mean probe ratio for Y of 0.17 (95% CI,
0.140.21) and a normal mean probe ratio for X. A nor-
mal mean probe ratio for X indicates that the decrease of
Y is not related to the presence of maternal contamination
in this male sample. Case 1 is illustrated as an extreme (*)
in the box plot in Figure 1 (with a mean probe ratio of
more than three box-lengths from the boundaries of the
box) and indicative for a mosaic 45,X/46,XY.
Case 2: STC villi showed a mosaic karyotype 45,X[5]/
47,XXX[1] and LTC villi showed a non-mosaic triple X
karyotype. I-FISH of STC nuclei resulted in a mosaic
monosomy X/disomy X/trisomy X in 68%, 3%, and 9% of
the cells, respectively. The MLPA results showed a de-
creased mean probe ratio for X of 0.80 (95% CI,
0.700.90). The ratio is increased for the expected value
of 0.5 for a monosomy X and decreased for the expected
ratio of 1.0 for a disomy and, therefore, indicative for a
mosaic 45,X/46,XX. Case 2 is illustrated as an outlier ‘o’ in
the box plot in Figure 1 with a mean probe ratio between
1.5 and 3 box-lengths from the boundaries of the box.
Case 3: STC villi showed a mosaic karyotype
47,XY,21[2]/46,XY[5] and LTC villi showed a non-mo-
saic trisomy 21 karyotype. I-FISH of STC nuclei resulted
in a mosaic trisomy 21/disomy 21 in 76% and 24% of the
cells, respectively. The mean probe ratio for chromosome
21 was increased to 1.24 (95% CI, 1.021.46). Inspec-
tion of individual probe ratios of this chromosome showed
an increase for all individual probes indicative for a mo-
saic trisomy 21. There was discordance between the
MLPA results and the results of TK of the LTC villi: the
expected value of 1.5 was not within the 95% CI.
Case 4: LTC villi showed a mosaic karyotype 45,X[3]/
46,XX[27] and STC villi showed a normal female karyo-
type. I-FISH of STC nuclei showed disomy X in 95% of the
nuclei. The MLPA resulted in normal mean probe ratios of
all target chromosomes (mean probe ratio  0.89, 95%
CI 0.800.99, this value is in the gray zone and inter-
preted as normal). Follow-up cytogenetic analysis of am-
niotic fluid cells was normal, indicating that the abnormal
cell line was probably confined to the placenta and the
LTC (cpm type II).
Case 5: LTC villi showed a mosaic karyotype of a
low-grade mosaicism 47,XY,13[2]/46,XY[27] and STC
villi showed a normal male karyotype. I-FISH of STC
nuclei resulted in a test failure. The MLPA resulted in
normal mean probe ratios of all target chromosomes.
Follow-up cytogenetic analysis of amniotic fluid cells was
normal, indicating that the abnormal cell line was con-
fined to the placenta and the LTC (cpm type II).
Table 1. Results of Traditional Karyotyping of STC, LTC, and Interphase FISH for One of the Target Chromosomes in Seven
CVS, Including Mosaic and Pseudomosaic Cases
Case
no
Referral
reason
Gestational
weeks STC karyotype
STC I-FISH
(% in 100 nuclei) LTC karyotype
Diagnosis
amniocentesis
Mosaicism level
(STC/LTC)
CPM
type
1 US-abn 21 45,X2	/46,XY1	 Test failure 46,XY29	 n.a. II/
2 US-abn 11 45,X5	/47,XXX1	 Monosomy X (88) 47,XXX29	 n.a. II/
Disomy X (3)
Trisomy X (9)
3 US-abn 13 47,XY,212	/
46,XY5	
Disomy 21 (76)
Trisomy 21 (24)
47,XY,2129	 n.a. II/
4 MA 11 46,XX4	 Monosomy X (5)
Disomy X (95)
45,X3	/46,XX27	 46,XX /II II
5 RIS 13 46,XY4	 Test failure 47,XY,132	/
46,XY27	
46,XY /II II
6 DNA 11 45,X3	/46,XX1	 Monosomy X (26)
Disomy X (74
45,X1	/46,XX28	 46,XX II/I III
7 US-abn 11 46,XY12	 Disomy 18 (100) 47,XY,1829	 n.a. /
MA, maternal age 35 years; CPM II, confined placental mosaicism type II; CPM III, confined placental mosaicism type III; US-abn, ultrasound
abnormality; RIS, at risk for Down after first trimester screening; n.a., not available (not performed); STC, short-term culture; LTC, long-term culture;
DNA, primary reason for invasive testing was the presence of a familial DNA mutation.
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Case 6: both STC and LTC villi showed a mosaic karyo-
type 45,X/46,XX. I-FISH of STC nuclei confirmed a mosaic
monosomy X/disomy X in 26%and 74%of the cells, respec-
tively. The MLPA resulted in a slight decrease of all probe
ratios for the X chromosome of 0.90 (95% CI, 0.830.96).
Follow-up cytogenetic analysis of amniotic fluid cells was
normal, indicating that the abnormal cell line was confined
to the placenta, both the STC and LTC (cpm type III).
Case 7 showed a complete discrepancy between STC
and LTC: the STC showed a 46,XY and the LTC a
47,XY,18 karyotype. The MLPA resulted in a slight in-
crease of the mean probe ratio for chromosome 18 of
1.18 (95% CI, 1.081.28). The MLPA results of DNA from
whole villi were compared to the results of the enzymat-
ically dissociated cell pools (Table 3). The mean probe
ratios for chromosome 18 in fraction C of both methods
showed a 95% CI including the value of 1.0, indicating
that the cell pool isolated in fraction C represented a pool
of cytotrophoblastic cells. The mean probe ratios for
chromosome 18 in fraction M of both methods showed a
95% CI including the value of 1.5, indicating that the cell
pool isolated in fraction M represented cells from the
mesenchymal core. Fraction T, a mixture of fraction C
and M (1:1), yielded results indicative for a mosaic tri-
somy 18, using both methods.
We conclude that these modified protocols for CVS
preparation have resulted in an accurate representation
of the cytotrophoblast layer and the mesenchymal core,
which is in full concordance with the results obtained by
karyotyping of STC and LTC.
Abnormalities Undetectable by MLPA
In six samples abnormalities were revealed by TK that
remained undetected by MLPA. These included three
samples with a familial chromosomal rearrangement, two
samples with a mosaicism with an extra marker chromo-
some with no clinical relevance (reason for referral nuchal
translucency and advanced maternal age) and one sam-
ple with a mosaic trisomy 10 (reason for referral ad-
vanced maternal age). Follow-up by ultrasound in this
latter pregnancy revealed an oligohydramnion.
Discussion
The suitability of the MLPA test on CVS as a replacement
for TK in the detection of prevalent aneuploidies of
chromosomes 21, 18, 13, X, and Y was assayed in 152
samples. By doing so, we found a complete concor-
Table 2. Overview of the Chromosome Mean Probe Ratios in Seven Mosaic Cases after Preparation of Whole Villi with
Proteinase K Treatment
Case STC karyotype LTC karyotype Mean probe ratios target chromosomes (95% CI)
1 45,X2	/46,XY1	 46,XY29	 #13: 1.00 (0.901.09)
#18: 0.97 (0.941.01)
#21: 1.04 (0.951.13)
#X: 0.52 (0.480.56)
#Y: 0.17 (0.140.21)
2 45,X5	/47,XXX1	 47,XXX29	 #13: 1.04 (0.981.10)
#18: 0.93 (0.821.04)
#21: 1.05 (0.911.19)
#X: 0.80 (0.700.90)
#Y: 
3 47,XY,212	/46,XY5	 47,XY,2129	 #13: 0.89 (0.621.16)
#18: 0.93 (0.751.10)
#21: 1.24 (1.021.46)
#X: 0.55 (0.450.65)
#Y: 0.43 (0.340.52)
4 46,XX4	 45,X3	/46,XX27	 #13: 1.00 (0.841.15)
#18: 0.97 (0.831.10)
#21: 1.07 (0.931.21)
#X: 0.89 (0.800.99)
#Y: 
5 46,XY4	 47,XY,132	/46,XY27	 #13: 1.02 (0.911.13)
#18: 0.97 (0.891.05)
#21: 1.02 (0.941.11)
#X: 0.49 (0.450.52)
#Y: 0.48 (0.460.50)
6 45,X3	/46,XX1	 45,X1	/46,XX28	 #13: 1.05 (0.961.13)
#18: 0.96 (0.901.03)
#21: 1.01 (0.921.10)
#X: 0.90 (0.830.96)
#Y: 
7 46,XY12	 47,XY,1829	 #13: 0.91 (0.830.99)
#18: 1.18 (1.081.28)
#21: 0.92 (0.850.99)
#X: 0.51 (0.470.56)
#Y: 0.45 (0.350.54)
#, chromosome.
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dance between the MLPA and TK results for the diagno-
sis of all euploidies and non-mosaic aneuploidies, re-
spectively, yielding an absolute specificity and sensitivity
of the MLPA test of 100%. However, a reliable prenatal
diagnosis based on CVS may be complicated by several
factors related to the cellular composition of CVS tissue,
which at the cytogenetic level may be expressed as
(pseudo)mosaicisms and/or maternal contaminations.
Between 1 and 2 percentage of the CVS karyotypes is
mosaic, and in more than 80% of the cases the mosa-
icism is confined to the placenta.12,13 Mosaicism for tri-
somies 21, 18 and 13 have been reported to occur in
0.26% of CVS.14 It is important to bear in mind that
mosaicisms for one of these target chromosomes may
also extend into the fetal cell lineages and, as such, they
must be considered as risk factors for fetal abnormalities.
Therefore, it is relevant to establish the detection level of
the MLPA test in mosaic cases. We found that all mosaics
tested exhibited a mean probe ratio outside the 95% CI,
and that all individual probes of the target chromosomes
involved yielded abnormal MLPA results.
The mosaics in our study were only detected by MLPA
if the abnormal cell line was present in the STC. This
result suggests that proteinase K digestion of whole villi
results in an over-representation of DNA from cytotropho-
blastic cells and, as such, closely resembles STC cell
DNA. This notion is in line with previous studies demon-
strating the cellular complexity of CVS tissues and the
relevance of CVS preparation methods for molecular test-
ing to minimize the risk of false-positive or -negative
results.15,16 As such, MLPA analysis of CVS on DNA
isolation of whole villi digested with proteinase K as pre-
sented here, is only appropriate as a replacement for TK
of STC villi. In case 7, in which the abnormal cells were
confined to the LTC, the MLPA result for chromosome 18
was indicative for a mosaic trisomy 18, with a 95% CI of
1.081.28. Neither 1.0 or 1.5 was included in the 95% CI.
This indicated that only a small proportion of the cells
digested with proteinase K was of mesenchymal origin. In
the other two cases, with an abnormality confined to the
LTC (case 4 and 5), this phenomenon was not observed
probably because the abnormalities in the LTC were
present as low-grade mosaicisms and, therefore, were
not observed in the MLPA results.
In case 7, we tested two different methods for enzy-
matic dissociation of the villi to obtain cells from both the
cytotrophoblast and the mesenchyme cell lineages. From
our data, we conclude that these two methods resulted in
proper representations of the cytotrophoblast layer and
the mesenchymal core, and that the MLPA results ob-
tained are in concordance with the results obtained by
karyotyping of STC and LTC, respectively. Enzymatic
dissociation with trypsin/EDTA followed by collagenase
showed that the total cell population (fraction T) con-
sisted predominantly of cells from the mesenchymal
core. This notion was confirmed by the MLPA electro-
pherogram from fraction C. Digestion with collagenase
followed by trypsin/EDTA gave the best results, repre-
senting a total cell population (fraction T) with a distribu-
tion of 60% cytotrophoblastic layer and 40% mesenchy-
mal core cells. QF-PCR results obtained with this CVS
preparation method were consistent with the presence of
mesenchyme and cytotrophoblast cells in almost equal
proportions.8 Recently, it was proposed by Mori et al that
the cytotrophoblast layer of chorion villi becomes thinner
during gestation, resulting in a gradual over-representa-
tion of the mesenchymal lineage.17 Since in case 1 we
found that the CVS in the 21st week of gestation displayed
MLPA results representative of the cytotrophoblast
lineage, we could not confirm this latter notion.
The potential presence of maternal cell contamination
(MCC) poses a serious risk for prenatal misdiagnosis.18
We have taken into account that MCC in female samples
cannot be detected by MLPA (see material and meth-
ods). In the male samples tested by MLPA, however, no
evidence was found for the presence of maternal con-
tamination. Additionally, we tested two of the male DNA
samples for the presence of MCC using another PCR-
based system (AmpFLSTR Identifiler Kit, Applied Biosys-
tems). Again, we failed to obtain any evidence for MCC.
It appears that the MCC problem can be minimized if
maternal deciduas are carefully removed from the villi
Table 3. MLPA Results of CVS (Case 7) with STC 46,XY and LTC 47,XY,18 Using Three Different Sample Preparation Methods
Sample preparation method
Mean probe ratios
(95% CI) fraction C
Mean probe ratios
(95% CI) fraction M
Mean probe ratios
(95% CI) fraction T
Whole villi proteinase K treatment - - #13: 0.91 (0.830.99)
#18: 1.18 (1.081.28)
#21: 0.92 (0.850.99)
#X: 0.51 (0.470.56)
#Y: 0.45 (0.350.54)
Enzymatic dissociation #13: 1.00 (0.901.10) #13: 0.82 (0.770.87) #13: 0.96 (0.861.06)
(coll, tryp/EDTA) #18: 1.00 (0.861.14) #18: 1.44 (1.351.54) #18: 1.16 (1.011.30)
#21: 1.02 (0.891.14) #21: 0.80 (0.750.86) #21: 0.90 (0.811.00)
#X: 0.49 (0.410.58) #X: 0.45 (0.430.47) #X: 0.49 (0.420.57)
#Y: 0.51 (0.450.58) #Y: 0.42 (0.330.50) #Y: 0.47 (0.370.57)
Enzymatic dissociation #13: 0.94 (0.741.13) #13: 0.84 (0.750.93) #13: 0.86 (0.810.91)
(tryp/EDTA, coll) #18: 0.92 (0.801.05) #18: 1.41 (1.261.57) #18: 1.37 (1.301.44)
#21: 1.17 (0.991.36) #21: 0.81 (0.750.88) #21: 0.82 (0.780.86)
#X: 0.59 (0.390.78) #X: 0.44 (0.390.49) #X: 0.46 (0.410.51)
#Y: 0.60 (0.310.90) #Y: 0.43 (0.330.53) #Y: 0.45 (0.360.54)
#, chromosome; tryp, trypsin; coll, collagenase.
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and/or if sample (DNA) preparation procedures are thor-
oughly optimized. Nevertheless, we suggest that valida-
tion studies are required to determine a further assess-
ment of MCC as potential cause of misdiagnosis in
prenatal testing of CVS. Enzymatic dissociation of CVS
yields cell pools representative for the cytotrophoblast
layer and mesenchymal core separately. Therefore, rapid
aneuploidy testing with MLPA on these cell pools is com-
parable to karyotyping of STC and LTC.
Although QF-PCR has the same inherent limitations as
MLPA in that it will not detect structural chromosome
aberrations1,19 it is sensitive for the detection of MCC and
triploidy (69,XXX). In reverse, MLPA has the advantage of
being able to assess the copy number of up to 50 loci in
a single assay. As such, MLPA can easily be extended to
other genomic regions of known clinical relevance20 and
can also be used as a highly efficient technique for the
detection of subtelomeric imbalances.21 The MLPA tech-
nology involves ligation of probes corresponding to a
chromosome-specific sequence that is unique within the
genome. In contrast to polymorphic loci used for QF-
PCR, these chromosome-specific sequences show little
or no variation, which avoids non-informativeness of the
targeted sequences. Therefore, the MLPA technology
may be well-suited for combining speed and targeted
testing of specific chromosomal inter- and/or intragenic
regions. Until recently, rapid aneuploidy detection was
mostly performed by I-FISH. MLPA and QF-PCR have
some advantages over I-FISH, ie, the tests are less labor-
intensive, more cost-effective and/or better suited for
high throughput analyses. QF-PCR and MLPA are con-
sidered to be valid alternatives to karyotyping for specific
referral reasons, although some clinically significant ab-
normalities will remain undetected. In a retrospective
study of 3700 CVS of women with referral reason elevated
maternal age, we determined that for every 1000 CVS
performed up to 25 chromosomal aberrations, of which
six with potential clinical significance, would remain un-
detected if MLPA were to replace TK (unpublished data).
As far as the clinical relevance of these anomalies is
concerned, it should be borne in mind that 70% of the
(structurally) unbalanced chromosomal anomalies lead
to intrauterine death or miscarriage before birth, and/or
are associated with abnormalities detectable by
ultrasound.22
The development and implementation of additional
novel molecular-cytogenetic techniques, such as array
CGH, is continuously increasing the resolution of the
detection of chromosome abnormalities.23 In prenatal di-
agnostics array CGH may be applied to pregnancies with
ultrasound abnormalities and a normal karyotype. How-
ever, retrospective validation studies have indicated that
more insight into normal versus abnormal copy number
variation within the human genome24,25 and a compre-
hensive detection of mosaicisms is required before such
a technology can be applied into routine prenatal diag-
nostic care.
We conclude that MLPA is a powerful technique for the
detection of aneuploidies of chromosomes 21, 18, 13, X,
and Y in CVS. In addition, we conclude that DNA extrac-
tion methods for CVS have a major impact on the genetic
make-up of the DNA pool and affect the reliability of the
molecular diagnosis of aneuploidies. In anticipation of
molecular targeted testing for prevalent aneuploidies in
CVS, we have designed a laboratory flowchart (Figure 2).
In this flowchart, the implementation of rapid aneuploidy
detection is based on DNA extracted from the cytotro-
phoblasts and the mesenchymal core, respectively. In
contrast to Gerdes et al26 concordant abnormal results in
these duplicate measurements are considered as final
test results, irrespective of whether an abnormality is
detected by ultrasound or serum screening.
Figure 2. Laboratory flowchart for integrating rapid aneuploidy detection
(RAD) in CVS into the cytogenetic diagnostic service. Approximately 30 mg
of cleaned villi is split into three fractions (
10 mg each). Two independent
cell preparation procedures based on enzymatic digestion with collagenase
and/or trypsin/EDTA are performed on fractions I and II to obtain suspen-
sions from cytotrophoblasts (fraction C) and the mesenchymal core (fraction
M), separately. A small amount of fraction M is used for LTC. Fraction III is
stored for back-up. DNA is extracted from fractions C and M and RAD by
MLPA or QF-PCR are assayed independently. The blue and red arrows
indicate the routing for RAD as stand-alone test and the routing for TK,
respectively. In this flow chart, TK of the STC is replaced by RAD on DNA
from the cytotrophoblast fraction. Discordant results with RAD between
fractions C and M or test failures is indicative for TK of the LTC or a repeat
experiment using back-up fraction III. When the results of RAD are abnor-
mal, follow-up karyotype analysis is performed to confirm the nature of the
aneuploidy.
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Taken together, we conclude that MLPA as targeted
stand-alone CVS test in pregnancies with an increased
risk for Down syndrome is a fast and reliable alternative
for traditional karyotyping on STC and LTC.
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